172229-93-5

Basic information

• Product Name: 2-CHLOROPIPERIDINE
• Synonyms: 2-CHLOROPIPERIDINE
• CAS NO: 172229-93-5
• Molecular Formula: C5H10ClN
• Molecular Weight: 119.59
• Mol File: 172229-93-5.mol

Chemical Properties

• Boiling Point: 160.5±33.0 °C(Predicted)
• Appearance: /
• Density: 1.06±0.1 g/cm3(Predicted)
• PKA: 7.55±0.10(Predicted)
• CAS DataBase Reference: 2-CHLOROPIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CHLOROPIPERIDINE(172229-93-5)
• EPA Substance Registry System: 2-CHLOROPIPERIDINE(172229-93-5)

Safety Data

• Hazardous Substances Data: 172229-93-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloropiperidine is used as a synthetic intermediate for the development of new pharmaceutical compounds, leveraging its reactivity to form complex molecular structures that can address specific medical needs.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Chloropiperidine is employed as a precursor in the synthesis of various agrochemicals, contributing to the development of effective crop protection agents and other agricultural products.
Used in Organic Synthesis:
2-Chloropiperidine is utilized as a versatile building block in organic synthesis, enabling the creation of a wide range of heterocyclic compounds with diverse applications across different industries.
Used in Chemical Research:
As a highly reactive compound, 2-Chloropiperidine is also used in chemical research to explore new reaction pathways and develop innovative synthetic methods, further expanding its utility in the chemical sciences.

Upstream product

• 110-89-4 piperidine 

Relevant articles and documents

Exploration of flexible phenylpropylurea scaffold as novel cardiac myosin activators for the treatment of systolic heart failure

A series of flexible urea derivatives have been synthesized and demonstrated as selective cardiac myosin ATPase activator. Among them 1-phenethyl-3-(3-phenylpropyl)urea (1, cardiac myosin ATPase activation at 10?μM?=?51.1%; FS?=?18.90; EF?=?12.15) and 1-benzyl-3-(3-phenylpropyl)urea (9, cardiac myosin ATPase activation?=?53.3%; FS?=?30.04; EF?=?18.27) showed significant activity in?vitro and in?vivo. The change of phenyl ring with tetrahydropyran-4-yl moiety viz., 1-(3-phenylpropyl)-3-((tetrahydro-2H-pyran-4-yl)methyl)urea (14, cardiac myosin ATPase activation?=?81.4%; FS?=?20.50; EF?=?13.10), and morpholine moiety viz., 1-(2-morpholinoethyl)-3-(3-phenylpropyl)urea (21, cardiac myosin ATPase activation?=?44.0%; FS?=?24.79; EF?=?15.65), proved to be efficient to activate the cardiac myosin. The potent compounds 1, 9, 14 and 21 were found to be selective for cardiac myosin over skeletal and smooth myosins. Thus, these urea derivatives are potent scaffold to develop as a newer cardiac myosin activator for the treatment of systolic heart failure.

Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure

The present invention relates to a compound having a cardiotonic activating function and a pharmaceutical composition containing the same. The composition comprising the compound according to the present invention is effective in preventing or treating heart failure. In addition, the compound is represented by chemical formula 2 or is pharmaceutically acceptable salt thereof.COPYRIGHT KIPO 2016

Compounds with cardiac myosin activating function and pharmaceutical composition containing the same for treating or preventing heart failure

Disclosed are a compound having cardiotonic activity and a pharmaceutical composition containing the same, and the composition containing the compound, according to the present invention, is useful for preventing and treating heart failure.COPYRIGHT KIPO 2016

Enantioselective, palladium-catalyzed α-arylation of N-Boc pyrrolidine: In situ react IR spectroscopic monitoring, scope, and synthetic applications

A comprehensive study of the enantioselective Pd-catalyzed α-arylation of N-Boc pyrrolidine has been carried out. The protocol involves deprotonation of N-Boc pyrrolidine using s-BuLi/(-)-sparteine in TBME or Et2O at -78 °C, transmetalation with ZnCl2 and Negishi coupling using Pd(OAc)2, t-Bu3P-HBF4 and the aryl bromide. This paper reports several new features including in situ React IR spectroscopic monitoring of the process; use of (-)-sparteine and the (+)-sparteine surrogate to access products with opposite configuration; development of a catalytic asymmetric lithiation-Negishi coupling reaction; extension to a wide range of heteroaromatic bromides; total synthesis of (R)-crispine A, (S)-nicotine and (S)-SIB-1508Y via short synthetic routes; and examples of α-vinylation of N-Boc pyrrolidine using vinyl bromides exemplified by the total synthesis of naturally occurring (+)-maackiamine (thus establishing its configuration as (R)). In this way, the full scope and limitations of the methodology are delineated.